Catalog No.
RHA19902
Species reactivity
Human
Host species
Mouse
Isotype
IgG1
Clonality
Monoclonal
Tested applications
IP: 1:100-1:200, WB: 1:500-1:1000
Target
BRG1-associated factor 250, OSA1, ARID domain-containing protein 1A, Osa homolog 1, BRG1-associated factor 250a, hOSA1, C1orf4, SMARCF1, AT-rich interactive domain-containing protein 1A, SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin subfamily F member 1, BAF250, SWI/SNF complex protein p270, ARID1A, SWI-like protein, hELD, B120, BAF250A
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
O14497
Applications
IP, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% Sodium Azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
R2T70
Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer., PMID:40446758
Biological and Clinical Relevance of Genetic Alterations in Peripheral T-cell Lymphomas., PMID:40416001
Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS)., PMID:39711167
VASN promotes the aggressive phenotype in ARID1A-deficient lung adenocarcinoma., PMID:39472811
Loss of microglial Arid1a exacerbates microglial scar formation via elevated CCL5 after traumatic brain injury., PMID:39350161
ARID1A-Deficient Tumors Acquire Immunogenic Neoantigens during the Development of Resistance to Targeted Therapy., PMID:39228255
Arid1a-dependent canonical BAF complex suppresses inflammatory programs to drive efficient germinal center B cell responses., PMID:39143398
Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors., PMID:38986529
Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma., PMID:38820888
Durable pembrolizumab response in metastatic MSS ARID1A-mutant undifferentiated carcinoma of the esophagus., PMID:38752926
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy., PMID:38704093
Molecular Features of HHV8 Monoclonal Microlymphoma Associated with Kaposi Sarcoma and Multicentric Castleman Disease in an HIV-Negative Patient., PMID:38612584
Comprehensive characterization of genomic features and clinical outcomes following targeted therapy and secondary cytoreductive surgery in OCCC: a single center experience., PMID:38606821
Establishment of a human ovarian clear cell carcinoma cell line mutant in PIK3CB but not PIK3CA., PMID:38573494
Targeting PI3K/AKT/mTOR and MAPK Signaling Pathways in Gastric Cancer., PMID:38339127
Arid1a-dependent canonical BAF complex suppresses inflammatory programs to drive efficient Germinal Center B cell responses., PMID:38313292
PLAU promotes growth and attenuates cisplatin chemosensitivity in ARID1A-depleted non-small cell lung cancer through interaction with TM4SF1., PMID:38229120
ARID1A loss induces P4HB to activate fibroblasts to support lung cancer cell growth, invasion, and chemoresistance., PMID:38100120
Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes., PMID:38055913
The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression., PMID:38050871
Role of AT-rich interaction domain 1A in gastric cancer immunotherapy: Preclinical and clinical perspectives., PMID:38041544
An Overview of Renal Cell Carcinoma Hallmarks, Drug Resistance, and Adjuvant Therapies., PMID:37927802
Emerging roles of Aurora-A kinase in cancer therapy resistance., PMID:37521867
Genomic characterization between HER2-positive and negative gastric cancer patients in a prospective trial., PMID:37325934
Characterization of Switch/Sucrose Nonfermenting Complex Proteins and Nestin Expression in a Cohort of Pediatric Central Nervous System Tumors., PMID:37036408
Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis., PMID:36963401
Waldenström Macroglobulinemia and Non-IgM-Type Lymphoplasmacytic Lymphoma Are Genetically Similar., PMID:36917966
A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy., PMID:36613564
Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma., PMID:36591227
Lymphocyte activation gene (LAG)-3 is a potential immunotherapeutic target for microsatellite stable, programmed death-ligand 1 (PD-L1)-positive endometrioid endometrial cancer., PMID:36509464
ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression., PMID:36435834
ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer., PMID:36117191
The Potential Predictive Biomarkers for Advanced Hepatocellular Carcinoma Treated With Anti-Angiogenic Drugs in Combination With PD-1 Antibody., PMID:35874743
A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium., PMID:35491267
The Role of ARID1A in the Nonestrogenic Modulation of IGF-1 Signaling., PMID:35320351
Advances in the Treatment of Hairy Cell Leukemia Variant., PMID:35178674
Pembrolizumab Achieves a Complete Response in an NF-1 Mutated, PD-L1 Positive Malignant Peripheral Nerve Sheath Tumor: A Case Report and Review of the Benchmarks., PMID:35020691
Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors., PMID:34673351
MicroRNA-directed pathway discovery elucidates an miR-221/222-mediated regulatory circuit in class switch recombination., PMID:34586363
Diagnostic and Therapeutic Approach in a Metastatic Vaginal Adenocarcinoma: A Case Report., PMID:34367146
Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation., PMID:34265801
Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma., PMID:34085048
ARID1A Deficiency Is Associated With High Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma., PMID:33860125
Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer., PMID:33782032
ARID1A knockdown in human endothelial cells directly induces angiogenesis by regulating angiopoietin-2 secretion and endothelial cell activity., PMID:33675830
Dramatic Response to Pembrolizumab Monotherapy in a Patient With ARID1A-Mutant Lung Adenocarcinoma: Case Report., PMID:33658161
Highly expressed Claudin18.2 as a potential therapeutic target in advanced gastric signet-ring cell carcinoma (SRCC)., PMID:33457012
Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma., PMID:33376237
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC., PMID:33315149
Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report., PMID:33292376
For research use only. Not for human or drug use.
